Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.

Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance. Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Citation

Roberto Mattioli, Andrea Ilari, Beatrice Colotti, Luciana Mosca, Francesco Fazi, Gianni Colotti. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Molecular aspects of medicine. 2023 Oct;93:101205

Mesh Tags

Substances

PMID: 37515939

search → result